Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic
March 31, 2020 09:00 ET
|
Chiesi USA, Inc.
Chiesi USA implemented increased health and well-being measures to support employees.Chiesi’s production line and supply chain are operating with no disruption across the network.Chiesi USA has...
Chiesi USA certified as a Great Place to Work® in 2019
March 02, 2020 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work® Certification for 2019 in the U.S. The...
Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020
February 27, 2020 08:00 ET
|
Chiesi USA, Inc.
Chiesi Group recently announced launch of new Chiesi Global Rare Diseases division to address significant unmet needs in rare diseasesDivision to advance research and build partnership opportunities...
Chiesi in the Community donates nearly $1 million in 2019
February 26, 2020 09:00 ET
|
Chiesi USA, Inc.
Chiesi’s CSR program increases contributions to the Triangle community and therapeutic areas CARY, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee) contributed more than...
Chiesi Group Announces Establishment of New Global Rare Diseases Division
February 06, 2020 07:00 ET
|
Chiesi USA, Inc.
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patientsChiesi Global Rare Diseases...
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2020
January 30, 2020 08:30 ET
|
Chiesi USA, Inc.
CARY, N.C., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee) announced today that the company has been named as a Top Employer in the United States for the fifth consecutive year. The...
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
January 13, 2020 08:30 ET
|
Chiesi USA, Inc.
Chiesi Group expands distribution network via acquisition for worldwide product rights.Chiesi Group will establish offices in Toronto, Canada. PARMA, Italy, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Chiesi...
Single-Inhaler Extrafine Triple Therapy of Inhaled Corticosteroid, Long-Acting B2-Agonist and Long-Acting Muscarinic Antagonist Therapy Improves Lung Function and Reduces Asthma Exacerbations(1)
October 01, 2019 11:41 ET
|
Chiesi USA, Inc.
Data from two randomized, double-blind, parallel-group, active-controlled studies on the efficacy and safety of single-inhaler triple therapy in adult patients with uncontrolled asthma is published in...
Chiesi and Durham Bulls Partnership Culminates in $15,000 to Triangle Nonprofits
September 04, 2019 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- As the Durham Bulls faced off against the Gwinnett Stripers on August 31, Chiesi (key-A-zee), a Cary-based specialty pharmaceutical company, sealed its...
Chiesi Group confirms positive trend to date for 2019
July 09, 2019 09:00 ET
|
Chiesi USA, Inc.
The latest available statistics reveal that, during the first six months of the year, overall revenues increased by 11.6% vs the first 6 months of 2018These results confirm 2019 to be a year...